Related Experiment Videos
Folate-targeted non-viral DNA vectors for cancer gene therapy
1CRC Institute for Cancer Studies, University of Birmingham, Vincent Drive, Birmingham, B15 2TA, UK. wardcm@hotmail.com
Abstract:
The vitamin folic acid exhibits high affinity for the endocytosed, membrane-bound folate receptor. Conjugation of folic acid via its gamma-carboxyl group to various macromolecules results in binding to, and endocytosis into, cells expressing the folate receptor. The folate receptor is overexpressed on a wide range of cancers, therefore folic acid has been investigated as a targeting ligand for the specific delivery of therapeutic compounds to cancer cells. This review will introduce folate-targeting of macromolecules to cancer cells in vitro and in vivo, and discuss the accumulation of such compounds in non-target tissues in vivo. Folate-targeting of non-viral DNA vectors in vitro and in vivo will be discussed in detail, with particular emphasis on the recent advances in this field.
Insights
Folic acid targets cancer cells by binding to folate receptors, enabling the delivery of therapeutic compounds. This review explores folate-targeting strategies for cancer therapy and potential off-target accumulation.
Area of Science:
- Biochemistry
- Oncology
- Nanotechnology
Background:
- Folic acid binds to folate receptors, which are overexpressed on many cancer cells.
- This interaction facilitates cellular uptake (endocytosis) of folate-conjugated substances.
- Folate receptors present a potential target for selective cancer cell delivery.
Purpose of the Study:
- To review the use of folic acid as a targeting ligand for delivering macromolecules to cancer cells.
- To discuss the in vitro and in vivo application of folate-targeted therapies.
- To examine the accumulation of these compounds in non-target tissues.
Main Methods:
- Review of literature on folate-targeted delivery systems.
- Analysis of studies involving in vitro and in vivo experiments.
- Focus on folate-targeted non-viral DNA vectors.
Main Results:
- Folic acid conjugation enables targeted delivery of macromolecules to folate receptor-expressing cancer cells.
- Folate-targeting has shown promise in both in vitro and in vivo cancer models.
- Accumulation in non-target tissues is a key consideration for in vivo applications.
Conclusions:
- Folate-targeting offers a promising strategy for specific cancer therapy.
- Further research is needed to optimize delivery and minimize off-target effects.
- Advances in folate-targeted non-viral DNA vectors are significant for future applications.